http://www.allheadlinenews.com/articles/7011409961
Washington D.C. (AHN) - A breast cancer vaccine currently being tested in a Phase II trial at various hospitals has yielded positive results and is targeted towards women who've already had metastatic breast cancer.
The therapeutic breast cancer vaccine AE37 uses a peptide antigen of a cancer gene known as HER-2/neu. This gene/protein is present in many types of cells, but it is over-expressed in a high proportion of breast cancers as well as many others.
Researchers say that they are seeking to evaluate the efficacy of two anti-cancer vaccines targeted to the HER 2 protein, which is expressed in 60 to 70 percent of all breast cancers.
Researchers believe that if the woman if an immune responder, she has double the survival rates as compared to non-responder.